Radiomic phenotypes of oligometastatic non-small cell lung cancer

寡转移性非小细胞肺癌的放射组学表型

阅读:1

Abstract

BACKGROUND: Identifying biomarkers that optimize patient selection for ablative therapy in metastatic non-small cell lung cancer (NSCLC) remains an unmet need. In this study, we identified radiomic features associated with sustained oligometastatic and indolent NSCLC. METHODS: We curated a retrospective cohort of 167 patients (132 training/validation, 35 test) with treatment-naïve, metastatic NSCLC and pre-treatment positron emission tomography/computed tomography (PET/CT). We extracted radiomic features from the primary lesion and used Pearson's correlation to identify those associated with extent of metastatic disease. For a subset (n=83), we also identified features associated with overall survival (OS) using Cox proportional hazards models. RESULTS: We found that the inverse flatness was lower (r=-0.23; q=0.04) and surface area-to-volume ratio (SVR) was higher (r=0.24; q=0.04) in primary lesions for cases with more metastases. We further found that higher gray level variance on CT portends shorter OS [hazard ratio (HR) =1.84, 95% confidence interval (CI): 1.32-2.56, q=0.004; test c=0.74, 95% CI: 0.52-0.90]. Risk groups derived from these scores exhibited median survival times in the training set of 12.6 and >50 months (P=0.001) and in the test set of 13.8 and 32.7 months (P=0.06). This feature was determined primarily by inclusion of low-intensity voxels. CONCLUSIONS: This study identifies radiomic features of indolent NSCLC, demonstrating that flatter, higher surface area primary disease is associated with a greater number of metastases, and primary lesions with lower density representing lung parenchyma, airspace, or lower-density tumor portend shorter OS. These findings lay the groundwork toward identifying patients suitable for ablative radiotherapy despite the presence of metastatic disease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。